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 A biologic drug is a drug that is produced by a living organism. Biologic drugs 
are used to treat various medical conditions such as arthritis, diabetes, or certain forms of 
cancers due to their high potency and high selectivity of action. Drawbacks of biologics 
include their poor stability in the gastrointestinal tract and their poor absorption. In effect, 
this gives the drugs very low bioavailability and short therapeutic half-lives. To combat 
these obstacles, current delivery methods include subcutaneous injections at home or 
intravenous or intramuscular injections in a medical facility. 
The overall scientific goal of the research was to utilize subcutaneous needle 
injection methodology used for parenteral systemic biologic drug delivery to solve the 
problem of delivering biologics orally for treating diseases like diabetes, arthritis, or 
cancers. Previous prototype tissue attachment mechanism (TAM) systems have shown 
tissue attachment in vivo, without the delivery of a drug. The methodology of this study 
was to use the same successful device but integrate an osmotic pump and a hypodermic 
needle to deliver a drug after attachment to the intestine. The delivery of the drug was 
deemed successful based on the drug's concentration in blood samples.  
The integrated TAM and drug delivery needle were designed, tested, and 
integrated on the benchtop until consistent successful drug delivery results were obtained. 
Once the device reliably delivered drug on excised tissue, it was tested in vivo on six 
 
 
swine for systemic drug delivery. The first study had shorter than expected TAM 
attachment times causing minimal drug to be delivered, but the methodology of the study 
was learned. After improving the device and study setup, a second in vivo study was 
performed on another six swine. The study showed much stronger evidence of drug 
delivery. Both positive controls and one of the three experimental groups showed 
systemic drug delivery. Both studies were a methods development study, so the number 
of pigs in the results did not meet the power for statistical significance. 
Also, in this work, a theoretical osmotic pump was designed to be integrated with 
the TAM and full capsule. Although not actually fabricated, the osmotic pump would be 
fabricated using the same material and ratio of drug to total volume as a commercial 
osmotic pump. The commercial osmotic pump was tested in a swine small intestine and 
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Chapter 1: Introduction 
1.1  Biological Drugs 
A biological drug (biologic) is a drug that is derived from any living organism 
such as humans, animals, or microorganisms [1]–[3]. Compared with conventional 
synthetic chemical drugs, biologics are relatively large and complex molecules [4]–[6]. 
They are made up of proteins, carbohydrates, nucleic acids, or a complex composite of 
these substances [1], [7], [8]. Biological drugs are used to treat various medical 
conditions such as rheumatoid arthritis, diabetes, or forms of cancers due to their high 
potency and high selectivity of action [2], [9]–[11]. Some of the most common biological 
drugs in the United States include adalimumab (Humira®) or rituximab (Rituxan ®) for 
rheumatoid arthritis, semaglutide (Ozempic®) or dulaglutide (Trulicity®) for treatment 
of diabetes, or trastuzumab (Herceptin®) for the treatment of breast cancer [9], [12]–[17].  
Although these drugs are effective, they must cross numerous obstacles before reaching 
the pathological site [18]. Specifically, biologics are poorly absorbed in the 
gastrointestinal (GI) tract because of their physio-chemical properties including size, 
charge, and hydrophilicity [19]–[22]. Frequently, an orally administered biologic may 
become inactive or less potent as it might be hydrolyzed or degraded enzymatically 
before reaching its targeted location [18], [23], [24]. After being degraded, it is excreted 
rapidly through the urinary system, leaving a minimal amount of drug at the targeted site 
[25]. Some biologics can be administered via a mucosal route, such as parathyroid 
hormone [26]. Non-protein biologics (such as steroid hormones) can be administered 
orally [27].  However, many biological therapeutics typically require parenteral delivery 
2 
which includes intravenous (IV) or intramuscular (IM) delivery in hospitals or 
subcutaneous (SC) injections at the patient’s home (e.g. via insulin pen) [28], [29].  
Unfortunately, IV, IM, and SC administrations can be painful or psychologically 
daunting causing many people to fear hypodermic needle placements and potentially drop 
out of their treatment [30]. It is estimated that 10% of the United States’ population has 
trypanophobia or needle phobia [31]. In a study performed on 12,582 people who were 
given the option of a free influenza vaccine via intranasal or SC injection, only 1,600 
people chose to be vaccinated. Of the 1,600 subjects, 97% of the people selected the nasal 
route. The subjects were asked the reason for choosing the nasal spray, and 14% 
responded with fear of injection [32].  
Aside from the fear of needles, injections are more challenging to use in a long-acting 
continuous drug input system outside of the hospital since the patients cannot 
continuously treat themselves [33]. When investigating new drug delivery methods, 
pharmacokinetics (PK) and pharmacodynamics (PD) are used to compare delivery 
methods [34]. Pharmacokinetics is the study and mathematical description of the 
relationship between the dose of a drug and its concentration in body fluids and tissues 
over time [35]. Pharmacodynamics, on the other hand, is the quantitative study of the 
relationship between drug exposure and pharmacologic or toxicologic responses [36]. 
Simply, PK represents “what the body does to the drug” and PD represents “what the 
drug does to the body”, specifically the targeted site, tissue, organ, etc. [37]. One of the 
most important pharmacokinetic parameters is bioavailability (F), which is the fraction or 
percent of an administered drug that reaches systemic circulation [38]. Many times, 
absolute bioavailability is used to compare different methods of drug delivery (i.e. oral 
3 








                  (1) 
Where the subscripts x and IV denote the delivery method of interest and intravenous 
delivery, respectively. Next, AUC means the area under the curve, which represents the 
area under the plasma concentration curve [40]. The area is defined by the plasma drug 
concentration on the y-axis and time on the x-axis. Figure 1 shows a generic example of 
an AUC comparing an oral administration to an IV administration. Lastly, D is the 
dosage of the drug administered, but many times dosages are the same between delivery 
methods, so it can be removed from the equation. 
 
 
Figure 1. An example graph showing the area under the curve (AUC) of an oral dose and 
an IV dose [41]. 
4 
 
Controlled drug delivery aims to deliver drugs to the target sites at desired rates and 
times, thus enhancing the drug efficacy, pharmacokinetics, and bioavailability while 
maintaining minimal side effects [42], [43]. To achieve a controlled drug delivery, many 
approaches are being explored, such as chemically modifying the biologic, encapsulating 
or protecting the drug, applying external transdermal microneedle patches, and more 
recently, novel oral drug delivery devices [44]–[47]. Ingestible drug delivery devices 
present possibilities for systemic delivery of biological drugs with or without chemical 
alteration [48], [49]. These easily ingestible devices can carry small electronics, 
mechanical components, mucoadhesive patches, or dissolvable microneedles which can 
deliver drug along the GI tract [50]–[53]. 
1.2  Oral Drug Delivery Devices 
In 2002, Eiamtrakarn et al. developed a gastrointestinal mucoadhesive patch system 
(GI-MAPS) to overcome the challenges associated with conventional drug delivery 
(Figure 2.) [54]. The patch system consisted of four layers: (I.) a backing layer made of a 
water-insoluble polymer to protect biological drugs from enzymatic hydrolysis, (II.) a 
surface layer made of a polymer sensitive to intestinal pH, (III.) a drug-carrying middle 
layer, and (IV.) an adhesive layer between the middle and surface layers to create a high 
concentration gradient between the patch and intestinal enterocytes. In this study, three 
different surface layer polymers were tested, hydroxypropyl methylcellulose phthalate 
(HP-55), Eudragit L100, and Eudragit S100. Each device was tested in three fasted 
beagle dogs using fluorescein as a model drug to track Tmax, (the time when plasma 
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concentration reaches its maximum level). Each surface polymer tested with the device 
demonstrated that the targeting of the device was obtained. In another trial, each device 
was loaded with 125 μg of recombinant human granulocyte colony-stimulating factor (G-
CSF) to detect an increase in total white blood counts. Each device was administered 
orally to four dogs and 125 μg of G-CSF was delivered intravenously to three dogs for 
comparison. In comparison to the IV injection, the total increase of white blood cells 
indicated the bioavailability of G-CSF was 23%, 5.5%, and 6.0% for Eudragit L100, HP-
55, and Eudragit S100 systems, respectively [55]. The bioavailability of the device was 
the highest value achieved compared with other oral drug delivery systems at the time 
[54].  
 
Figure 2. GI-MAPS oral device comprising mucoadhesive patches and an enterically 
coated capsule [54].  
A group from MIT developed an oral biological delivery system (Figure 3) inspired 
by a leopard tortoise’s ability to passively reorient [56]. The self-orienting millimeter-
scale applicator (SOMA) autonomously positions itself to interact with GI tissue. The 
device is designed as a monostatic body, meaning it only has one stable position. This is 
6 
accomplished by a shifted center of mass and a high-curvature upper shell that enables 
self-orientation to the preferred upright position. After correctly orienting itself, the 
device deploys a microneedle array manufactured from active pharmaceutical ingredients 
directly through the gastric mucosa while avoiding perforation. By using insulin as the 
model drug, SOMA was tested in rats and swine to demonstrate safety and efficacy. The 
study showed that the plasma insulin levels from SOMA were comparable to those with 
subcutaneous admission [56]. 
 
Figure 3. SOMA self-orienting to its stable position and delivering drug [56]. 
The same MIT group developed another biological drug delivery device termed 
the luminal unfolding microneedle injector (LUMI) pill (Figure 4) [53]. LUMI consists of 
three degradable arms spring-loaded into a capsule. Each arm consists of a dissolvable 
drug-loaded microneedle patch. The device utilizes a polymer coating, designed to 
dissolve at a pH greater than 5.5, in combination with a polyethylene glycol (PEG) 
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coating to encapsulate a compressed spring that propels the LUMI out of the capsule. 
After the device is propelled from the capsule, each arm stretches the tissue and presses 
the microneedle patches into the tissue wall, where they penetrate the epithelial barrier, 
dissolve and release the encapsulated drug [57]. The researchers used insulin as a model 
drug and demonstrated that LUMI provided a faster pharmacokinetic uptake profile and a 
systemic uptake greater than 10% of that of a subcutaneous injection over a 4-h sampling 
period [53].  
 
Figure 4. The luminal unfolding microneedle injector (LUMI) actuation scheme [53]. 
 Rani Therapeutics is a private-based company that is developing an ingestible 
drug delivery system named the RaniPill (Figure 5). From the outside, the Rani Pill 
appears to be a standard capsule, but several mechanisms occur after ingesting. After 
entering the GI tract, the outer capsule dissolves exposing a tiny valve that separates two 
chambers filled with citric acid and bicarbonate. Then the valve dissolves causing the two 
chemicals to combine which produces carbon dioxide. The carbon dioxide gas inflates a 
balloon-like structure which drives dissolvable sugar microneedles into the wall of the 
intestine. The needles then detach from the remaining capsule and slowly dissolve, 
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introducing the drug into nearby blood vessels. The remaining components either 
dissolve or pass through the body [58].  Rani Therapeutics is currently testing daily oral 
insulin pills in human trials [59].  
 
Figure 5. The RaniPill actuation process [59]. 
 
1.3  Previous Research and Approach 
 Although there have been several semi-successful oral biological drug delivery 
devices produced by multiple groups, they each lack the ability for long-term attachment 
(greater than 2 weeks). Terry et al had previously been developing a long-term ingestible 
capsule robot (ICR) for the use of active diagnostics, intervention, and bio-sensing 
(Figure 6) [60]. They designed this with the intention that if physicians can constantly 
monitor specific elements of the GI tract, better clinical diagnostics could be achieved. 
For example, the temperature and pH of the intestine have been considered two vital 
factors that control enzyme activity which thereby affect digestive function [61]. In 
addition to diagnostics, a long-term attachment may provide other possible functions such 




Figure 6. Schematic showing the noninvasive implantation of attachment mechanism on 
the mucosal lining of the GI tract via a long-term ingestible capsule robot (ICR). 
  Employing the same design, our current group wanted to use the ICR for systemic 
delivery of physically and chemically unaltered biological drugs into the submucosa layer 
of the small intestine. The use of existing, unmodified biological drugs eliminates the 
cost and complications associated with developing new drugs. It is estimated that new 
drug development can cost somewhere between $500 million to $2 billion [62], meaning 
delivery of unaltered biological drugs could save industries money and time. Despite 
having the capability for systemic drug delivery, the previous ICR had some drawbacks. 
The dimensions of that ICR were not within the standard ingestible capsule range and 
contained several electronic components unnecessary for drug delivery. The fabrication 
process was complicated therefore the device was not mass-producible. Furthermore, all 
previous optimizations were done on dead, excised porcine intestinal tissue lacking the 
dynamic properties of live tissue. In this current work, the TRL is developing a mass-
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producible, standard capsule sized ICR tailored for long-term drug delivery. The drug 
delivery ICR is designed so that it passively travels to the small intestine via digestive 
peristalsis after it is swallowed. The goal is for the ICR to deploy the drug-carrying 
payload into the submucosa via a novel tissue attachment mechanism referred to as the 
"TAM".  
Inspired by intestinal parasites, the system relies on suction or negative pressure 
for tissue attachment. Biomimicking the sucking action of a parasite, the TAM consists of 
an orifice with stainless steel needles angled down and inward, acting as the teeth of a 
parasite, referred to as the TAM needles (Figure 7A). The stainless steel orifice and 
needles are mounted on a 3D printed TAM body via ultraviolet (UV) glue. (Figure 7B). 
Upon reaching the small intestine, the TAM is ejected from the ICR and remains adhered 
to the mucosa for a prolonged period while maintaining intimate contact with the tissue. 
An advantage of using the TAM for long-term attachment is the lack of pain receptors 
along the GI tract [63]. One possible application enabled by this extended intimate 
contact with tissue is extended-release drug delivery. The payload could be contained 
inside the TAM unaltered and separate from the ICR, thus enabling the payload to be 
simple, small, and biocompatible. Like a subcutaneous injection, the drug may be 
injected directly through the submucosa layer, thus bypassing the barrier function of the 
small intestine wall.   
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Figure 7. A) TAM orifice and TAM needles. B) TAM Body 
 To maximize attachment reliability, my collaborator Sunandita Saker, designed 
and optimized a mass-producible miniaturized TAM suited for a drug delivery ICR. 
Based on previous research, attachment success and duration depends on multiple 
independent factors related to TAM geometry (orifice diameter, number of needles, 
needle angle, needle length, needle width), vacuum volume, and small intestine tissue 
location (duodenum, jejunum, or ileum) [60]. Sunandita implemented a factorial design 
of experiments in her research to screen and optimize the design with a reduced number 
of trials for optimal success. Concurrently, the drug delivery portion of the ICR was 
developed and is the main topic of this thesis. Due to the simultaneous development of 
the optimized TAM geometry, throughout this work the dimensions of the TAM change. 
Also, the ICR used in this research does not contain any electronics or robotic functions, 
therefore it will be referred to as the capsule. 
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1.4  Research Objectives 
The overall scientific objective of the research was to utilize subcutaneous needle 
injection methodology used for parenteral systemic biologic drug delivery to solve the 
problem of delivering biologics orally for treating diseases like diabetes, arthritis, or 
cancers. This was accomplished by showing proof-of-feasibility of biological drug 
delivery via needle injection into the small intestine. The first goal was to develop a 
prototype TAM that integrated a commercial off-the-shelf (COTS) drug delivery system 
for systemic administration of glucagon-like peptide 1 (GLP-1) or a suitable surrogate via 
the intestinal wall. Specifically, a custom needle was developed for administering drug to 
the submucosa of the small intestine. A COTS osmotic pump was then integrated with 
the custom needle and tested for its drug delivery performance using benchtop models. 
The injection needle and the COTS pump were incorporated into the TAM, and the entire 
system was tested in a live porcine model for long-term drug delivery using adalimumab 
as the administered biological drug.  
The second goal was to design (without physical implementation) a custom 
osmotic pump that is compatible with the capsule system. A custom osmotic pump was 
designed using dimensions and specifications from a commercial manufacturer of these 
types of pumps. The custom pump design met the criteria for use in the complete capsule 
system but was not fabricated or tested in this current work. 
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Chapter 2: Drug Delivery System 
2.1 Functional Requirements of Drug Delivery System 
1. Location of Delivery 
The drug shall be delivered to the small intestine, ideally near the ileum region. The 
ileum region is where most GLP-1 is naturally secreted from enteroendocrine cells (L 
cells). Systemic delivery shall be administered to the submucosa.  
2. Duration of Administration 
The drug injection needle and osmotic pump should deliver GLP-1 (or a suitable 
surrogate) for 4-7 days at a minimum bioavailability of 10%. 
3. Success Rate 
Although this project was designed to assess feasibility, we created a design that targets a 
success rate of greater than 90%, i.e. at least four days of sufficient drug is administered 
in 9 out of 10 TAM trials in different animals (to be studied in future work). 
4. Animal  
The TAM shall function properly in a fed, watered, and awake pig without harming one 
animal. 
5. Component Materials and Properties 
The drug injection needle and the osmotic pump will be made with non-toxic parts. The 
osmotic pump used in experiments will be a commercially available osmotic pump. 
6. MRI Compatibility  
The osmotic pump and drug delivery needle shall be compatible with MRI. 
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7. Cost  
The cost of the capsule system should be less than $50 (based on 50,000 units/year). 
8. Manufacturability 
The system shall be manufacturable in a timely fashion on a scale of 100,000 units/year. 
Note: this quantity is different from the cost quantity to make a conservative case in both 
categories. 
2.2 Initial design of the Drug Injection Needle 
The purpose of this task was to design and fabricate a custom injection needle for 
implementation on the TAM to administer a biological drug to the submucosa. The initial 
approach was to modify a 30-gauge brain infusion needle (BIN) available from Alzet 
(Figure 8). The cannula was a 3 mm long stainless steel tube with a 0.16 mm inner 
diameter and 0.31 mm outer diameter (the cannula was not hypodermic). The cannula 
was selected as a preliminary approach since it could easily be attached to the Alzet 
osmotic pumps that would be used for drug delivery later in this work. The cannula is 
attached to the osmotic pump via a thin, small, plastic tube referred to as a catheter in this 
work. The infusion kit was modified by removing the pedestal to expose the low-profile 
L-shaped steel tubing. The TAM and drug delivery needle required space in the capsule 
for tissue suction. To accommodate the BIN, a special capsule for benchtop testing was 
designed and 3D printed (Figure 9-11). The vacuum aspiration port was necessary to 
create a negative pressure but in the final design, the negative pressure will be carried on 
board.  After the capsule was created, varying lengths of BINs were inserted through the 
capsule hole and each BIN’s base was glued to the bottom of the capsule. The complete 
assembly is shown in Figure 12-15. 
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 A preliminary experiment was set up to determine if the BIN could deliver a drug 
into the submucosa of excised intestinal tissue. The goal of the experiment was to 
determine a criterion that showed drug delivery into the intestinal tissue with a needle. 
For the tests, drug injection needle lengths varied from 0.5 mm to 2.5 mm (the tip of the 
canula was 4.5 mm to 2.5 mm away from the top of the TAM body, respectively). In the 
experiment, intestinal tissue was placed over the orifice of the TAM and drug injection 
needle. Next, the vacuum valve was opened exposing the tissue to 600 μL of -25 mmHg 
air. The negative pressure causes the intestinal tissue to aspirate into the space of the 
capsule. When tissue is aspirated into the capsule, the TAM needles penetrate the mucosa 
layer causing a firm attachment to the intestinal wall. During the aspiration of the 
intestinal tissue, the drug injection needle could also penetrate the submucosa.  After a 
strong aspiration and attachment, colored water (mimicking drug) was pushed through 
the drug injection needle and potentially into the intestinal tissue by a syringe pump and 
catheter. Approximately 2 mL were injected into the intestinal tissue so that one could 
easily visualize delivery, fulfilling the goal of finding a criterion to confirm delivery. The 
experimental setup is shown in Figure 16.  
After the preliminary experiments with the BIN integrated with the device, it was 
decided using a 30-gauge needle to penetrate the submucosa and deliver a drug bolus was 
feasible (Figure 17 and Figure 18). This experimental setup was used later in this work 
and the results are explained in more detail. Although the Alzet BIN showed benchtop 
drug delivery, it proved difficult to modify due to size constraints, so it was decided to 
make custom drug injection needles using a 30-gauge needle. Another downside to using 
the BIN was its inconsistency in piercing the mucosa. This was likely due to the BIN 
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being a non-hypodermic needle, so succeeding experiments were tested with a 




Figure 8. Schematic of the brain infusion kit from ALZET. 
 




Figure 10. CAD design of a capsule compatible with the BIN (cross-section). 
 
Figure 11. CAD design of a capsule compatible with the BIN (bottom-view). 
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Figure 12. CAD assembly of a capsule with the BIN. 
 
Figure 13. CAD assembly of a capsule with the BIN (cross-section). 
 
 
Figure 14. Assembly of a capsule with the BIN. 
19 
 
Figure 15. Assembly of a capsule with the BIN (bottom-view). 
 





Figure 17. A representative image of BIN delivering a "drug" bolus. Colored (green) 
water was used in this benchtop study. 
 




Figure 19. A) ALZET's blunt canula (needle) and B) a beveled hypodermic needle. 
 
2.3  Alternative Designs for Drug Delivery 
 To achieve reliable drug delivery, alternative design concepts were brainstormed 
(Figure 21). The previously described bench-top experiments helped determine feasibility 
and gain knowledge of the newly introduced concepts. Designs 2-4 required the needle to 
connect to the osmotic pump via a catheter (or some other channel). In the concepts 
below, the designed osmotic pump is shaped like a torus and is explored later in Chapter 
3. The five alternative designs for attachment are described below and variations of the 





Figure 20. Concept model of capsule illustrating a torus-shaped osmotic pump. 
Design 1: Perpendicular Needle  
In the perpendicular needle design, the drug injection needle is within the torus-
shaped osmotic pump. The injection needle is connected directly to the osmotic pump 
with 2-4 ports. The needle perpendicularly pierces the tissue upon aspiration. This 
design was similar to the benchtop test described above with the BIN.  
Design 2: Spring-Loaded Needle Outside Capsule 
In the spring-loaded needle design, the injection needle is offset from the orifice 
of the TAM, therefore away from the aspirated tissue. The drug needle penetrates the 
tissue via a pre-loaded spring during the attachment sequence. The advantage of this 
design is that it mitigates the possible problem of reduced blood flow to aspirated 
tissue because the needle is outside the aspiration zone.  
Design 3: Dual-Purpose Needle 
In the dual-purpose needle design, the injection needle replaces one of the TAM's 
needles and thus has dual purposes: to perform tissue attachment as well as provide a 
channel for the drug. This concept would require no extra injection needles.  
Design 4: Spring-loaded Needle within Capsule 
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In the spring-loaded needle within the capsule design, the injection needle is 
within the capsule at some undetermined orientation. In this design, the needle 
approaches horizontally. The injection needle is spring-loaded and independent of 
tissue aspiration. 
Design 5: Drug pool through TAM hole 
In the drug pool design, the concept is to create a reservoir of drug between the 
pump and the tissue. The drug is pumped out of the osmotic pump over time and 
stored in a closed capsule to prevent leakage into the lumen. The drug then enters the 
submucosa through the channels created by the TAM needles. With this concept, 
there is no direct drug injection, therefore no need to rely on drug needle penetration 













     
Figure 21. Concept model of a 1) perpendicular drug injection needle, 2) spring-loaded 
drug injection needle, 3) dual-purpose drug injection needle, 4) spring-loaded drug 
injection needle within the capsule, 5) drug pool within the capsule 
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2.4 Down Selection Process 
To determine which approaches to drug delivery were better suited to the application, 
the six team members scored each design in a Pugh Matrix. After several iterations of 
scoring, the concept with the highest score was the “drug pool” concept. However, due to 
the novelty of this concept, it was decided to not use this idea in initial testing but rather 
use the second-highest scoring and third-highest scoring concepts, the dual-purpose 
needle, and the perpendicular drug injection needle, respectively.  
Below are the evaluation parameters and weights (Table 2 and Table 3) for the last 
iteration of the Pugh Matrix. The perpendicular drug injection needle was the reference, 
so it received “0” for every parameter. The devices were scored based on the following 
scale: 
+2: much better than the baseline. 
+1: somewhat better than the baseline. 
0: equal to the baseline. 
-1: somewhat worse than the baseline. 
-2: much worse than the baseline. 
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Table 1. Drug delivery evaluation criteria matrix with weights 
 Evaluation Parameters 
Weight 
(1,3,9) 
 Development risk/complexity   
1 Technical feasibility 9 
2 Development time 9 
3 
Development expense (technologies employed, cost to      
integrate) 3 
 Robustness of penetration   
4 Reliability of tissue penetration 9 
5 Risk of penetrating too far 9 
6 Needle engagement robustness 9 
 Robustness of drug delivery   
7       Bioavailability performance 9 
 Size profile   
8      Size Profile 9 
 Cost   
9 Part complexity, tolerances required 3 
10 Labor (manual vs automation) 3 
11 IP favorability 1 
12 Dead volumes and/or material use efficiency 1 
 Manufacturability   
13 Assembly complexity 9 
14 Manufacturability, chemical and/or wet processes 3 
15 Scalability 9 
 Durability   
16 Reliability over shelf life 9 



























1 9 0.0 -1.5 -1.0 -1.8 0.3 
2 9 0.0 -1.3 -1.0 -1.3 0.8 
3 3 0.0 -1.3 -1.3 -1.3 1.3 
 
4 9 0.0 1.5 1.2 0.2 -0.5 
5 9 0.0 -0.3 1.2 0.5 1.8 
6 9 0.0 0.5 1.3 0.2 -1.2 
 
7 9 0.0 1.2 0.0 0.3 -1.3 
 
8 9 0.0 -0.3 0.5 -0.5 0.3 
 
9 3 0.0 -1.8 0.5 -1.7 1.3 
10 3 0.0 -0.5 -0.2 -0.5 0.5 
11 1 0.0 0.0 0.8 0.0 0.5 
12 1 0.0 -0.7 0.8 -0.8 -0.5 
 
13 9 0.0 -1.8 0.2 -1.8 0.3 
14 3 0.0 -0.7 -0.5 -0.8 0.0 
15 9 0.0 -0.5 -0.5 -0.5 0.3 
 
16 9 0.0 -0.7 0.0 -0.7 0.0 
17 9 0.0 -0.5 -0.2 -0.2 0.7 
 Total 0.0 -8.8 1.8 -10.8 4.8 
 Weighed Total 0.0 -48.2 12.2 -64.8 24.5 
  Legend 
  
much worse worse neutral improved 
much 
improved 




The dual-purpose needle (Figure 22. A, C, and E) and perpendicular needle (Figure 
22 B, D, and F-H) TAMs were designed and created to be tested with intestinal tissue on 
the benchtop. All drug injection needles used in the experiment were 30-gauge 
hypodermic needles. The dual-purpose needle had the same dimensions as the TAM 
needles at the time, as shown in Figure 22 A and C. The needle was 3 mm long at a 30-
degree angle relative to the top of the TAM. The perpendicular needle concept had two 
different versions created, referred to as the non-flush perpendicular needle (Figure 22 F 
and H) and the flush perpendicular needle (Figure 22 G). The flush perpendicular needle 
design was designed to have a smaller profile after attachment. This design was 
introduced after preliminary successes with the non-flush perpendicular needle. In either 
design, the 30-gauge hypodermic needle is inserted through a 0.5 mm hole in the TAM, 
bent towards the center of the TAM, and then bent again up towards the top of the TAM 
orifice (Appendix B shows the full manufacturing process). For both versions, the 
vertical length of the needle could be modified if needed. After ad-hoc benchtop testing, 
each version performed best when the hypodermic needle was even with the top of the 
TAM orifice. To be at the orifice’s height, the vertical length of the non-flush and flush 







Figure 22. A) CAD design of dual-purpose needle TAM. B) CAD design of 
perpendicular needle TAM. C) Cross-section CAD design of dual-purpose TAM. 
D) Cross-section CAD design of perpendicular TAM. E) Top view of the dual-purpose 
needle TAM. F) Side view of perpendicular needles TAMs. 1 mm needle on the left and 
5 mm needle on the right. The heigh of the needles could be altered. G) Side view of 
perpendicular needle flush to TAM. H) Top view of perpendicular needles TAMs. 
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2.6 Benchtop Experiments 
Following the creation of the devices, they were tested with intestinal tissue on the 
benchtop. Each device was tested in the ileum and jejunum regions of the intestine. The 
ileum was selected for several reasons, its nutrient absorbent properties, thick wall layer, 
and is the longest section of the human small intestine [64], [65]. The thicker the tissue is, 
the easier it is to penetrate without perforating completely through the intestinal wall. The 
jejunum was also used to see how the devices would perforate the thin wall of the 
jejunum. The duodenum was excluded from the test because it had a similar thickness to 
the ileum but less nutrient absorbing properties. The setup and attachment sequence was 
the same as described earlier, Figure 16. However, with this setup, the TAM and drug 
injection needle could be removed from the aspiration system. This was a major 
advantage over the BIN assembly, creating a smaller attachment profile. After manually 
injecting the sham drug (colored water) through the drug delivery needle via a syringe, 
one of three results occurred: 1- The drug injection needle penetration was insufficient 
and did not deliver the sham drug (Figure 23); 2- The drug injection needle sufficiently 
penetrated (Figure 24) and formed a bolus of colored water within the intestinal tissue 
(Figure 25). Occasionally when the bolus was delivered, colored water was visible 
around the capillaries (Figure 25 and Figure 26); 3- The drug injection needle penetrated 
too far and perforated the tissue. Each device type was tested 10 times at the jejunum and 
ileum and recorded as a successful or unsuccessful delivery (Table 3). After running the 
test, the flush perpendicular needle performed the best at the ileum, followed by the other 
perpendicular device at the ileum. The dual-purpose device did not perform well at either 
location. Each failed perpendicular device drug delivery at the jejunum occurred because 
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the needle perforated too far. All other failures occurred because the needle did not 
penetrate enough.  
Table 3. Results of Benchtop Study. 
Needle Type Tissue Location
Number of Successful 
Deliveries (10 Trials)
Reason for Failures
Flush Perpendicular Ileum 10 N/A
Non-Flush Perpendicular Ileum 7 Penetration Short
Dual Purpose Ileum 3 Penetration Short
Flush Perpendicular Jejunum 6 Full Perforation
Non-Flush Perpendicular Jejunum 5 Full Perforation








Figure 24. Perpendicular needle delivering drug. 
 
 
Figure 25. Colored water is shown in/around vessels of the small intestine after delivery 
from the perpendicular drug injection needle. 
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Figure 26. Several boluses of colored water were delivered into the small intestine from 
the perpendicular needle. 
 
2.7 In vivo Experiment 1 
2.7.1 Introduction 
Based on the benchtop results, an in vivo experiment was designed. The flush 
perpendicular drug delivery needle (referred to simply as the perpendicular needle 
hereafter) was used in the ileum region. Adalimumab (PGN-001) was selected to be 
delivered based on the guidance of our sponsor, Progenity. Adalimumab is a biological 
drug used to treat arthritis and is detected in the blood at small concentrations: however, 
it is nonabsorbable in the small intestine, making it an appropriate surrogate drug to GLP-
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1. Essentially, adalimumab is only detected in plasma samples if it is injected into the 
submucosa. It does not show up on plasma samples if it is simply injected into the lumen 
of the intestine.  
2.7.2 Objectives 
1) Penetrate small intestinal tissue with the drug injection needle without 
gastrointestinal perforation 
2) Deliver drug systemically via the submucosa of the small intestine for at least four 
days. 
2.7.3 Hypothesis 
The drug delivery capsule will deliver non-absorbent biologics into the submucosa of 
the small intestine and systemically thereafter. This was a methods development study, so 
the number of pigs outlined in the procedure did not meet the power for statistical 
significance. 
2.7.4 Materials and Methods 
After selecting the perpendicular drug delivery needle as the method to deliver the 
drug, the design of the needle was slightly altered so that it had a smaller profile. This 
design was tested and confirmed with benchtop testing. The final TAM/drug delivery 
needle is shown in Figure 27. The capsule chamber was used to aspirate tissue and after 
attachment, the TAM was manually removed from the capsule, leaving behind only the 
TAM and drug delivery hypodermic needle. This device was attached via catheters to a 








Figure 28. Capsule chamber/TAM/drug delivery needles connected to a 200 ul osmotic 
pump via catheters. Note: The device is attached to the vacuum system. 
 
The 200 μL osmotic pumps were purchased from ALZET and were primed 
according to the manufacturer’s procedure [66]. This was done to ensure osmotic 
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pumping would begin as soon as the pump was placed into the intestine after the 
TAM/drug delivery needle was attached.  
During the study, we switched from a 7-day delivery pump to a 1-day delivery 
pump due to shorter than expected attachment times (results shown later in the chapter). 
By switching to the 1-day pump, the osmotic pump would ideally have had enough time 
to deliver all its volume into the intestine before TAM detachment.  
Experimental Design 
• Animal model:  Yorkshire-domestic cross 
• Animal size:  20-35 kg (8-10 weeks old) 
• Dose delivered:  20 mg adalimumab 
• Volume delivered via osmotic pump: 200 μL  
• Sample:  serum 
• Number of animals: 6 animals  
• Study duration:  14 days (7 delivery + 7 pharmacokinetics) or 7 days after device 
detaches 
• Sampling frequency:  0, 6, 12, 24 hours and then once daily to necropsy 
• Gross pathology 
• Histopathology of the site (H&E) 
 
Experimental Groups 
1) Negative control (n=1):  This pig had drug injected into the lumen of the small 
intestine via an osmotic pump for 7 days. There was no TAM/drug delivery needle in this 
animal, only an osmotic pump. 
2) Positive control (n=1): This pig had drug fully injected into the submucosa of 
the small intestine manually with a needle and syringe. 
3) Experimental groups (n=4): These pigs received injections into the submucosa 
of the small intestine using the drug delivery device with an osmotic pump sutured 
downstream of the intestine. The drug was injected after the tissue was aspirated into a 
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special "tissue capture mechanism" (TAM). In this study, the experimental groups were 
separated into: 
a. (n=2) 7-day drug delivery osmotic pumps  
b. (n=2) 1-day drug delivery osmotic pumps 
Surgery/Experimental Procedure 
Step 1. Weigh the animal, record weight (in lbs and kg). 
Step 2. Administer the anesthetics (TKX shot) and atropine (to decrease salivation). 
Step 3. Place the animal on the surgery table. Trim the hair over the abdomen of the pig 
and clean the skin with isopropyl alcohol and povidone-iodine to create a sterile field. 
Step 4. Once the pig is anesthetized, place a jugular catheter for blood samples. 
Step 5. Collect 1ml of jugular venous blood samples into an EDTA blood collection tube 
before capsule deployment. (t=0) 
Step 6. Cut the skin of the abdomen using scissors for several centimeters over the region 
of the intestinal tissue. 
Step 7. Bring and secure the desired intestinal tissue (duodenum, jejunum, or ileum) up 
into the incision field. 
Step 8. Cut open the intestine a few centimeters to gain access into the small intestine 
lumen. 
Step 9. Suture osmotic pump within the intestinal lumen. The osmotic pump is to be 
connected to the capsule device via a 15 cm catheter. 
Step 10. Once the osmotic pump is sutured in place (step 9 and step 10 can be reversed), 
place capsule inside the lumen of the intestine and aspirate tissue to allow for attachment.   
a. Place the device against the intestinal tissue and feels for intimate contact. 
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b. With no air pockets surrounding the device, open the vacuum valve. This will cause 
intestinal tissue to aspirate into the device (Figure 29). 
c. The attachment needles will now be attached to the intestinal tissue (through 
the submucosa but stopping before puncturing the serosa) Note: This was proven in 
previous experiments. 
d. Remove the device from the vacuum system (Figure 30). 
e. Over the next few days, the submucosa will die and slough off causing the 
device to naturally be released from the tissue. 
Step 11. Check for strong attachment by giving a slight tug on the capsule. Make note if 
it does not attach but continue to attempt attachment up to 5 times. 
Step 12. Once the capsule has successfully attached to the small intestine, seal the 
injection site with skin glue/sutures to prevent leakage of the intestinal fluid into the 
peritoneal cavity. Suture marker beads next to the attachment site to allow reference for 
X-ray (Figure 31). 
Step 13. Close the skin of the pig using sutures in a running fashion. 
Step 14. Give the animal a subcutaneous injection of buprenorphine (0.05 mg/kg) for 
analgesia. 
Step 15. Remove the swine from anesthesia and place it into a clean, warm area for 
recovery. 
Step 16. Using the indwelling jugular catheter, collect 1 ml of jugular venous samples 
into EDTA blood collection tubes at the following time points post capsule deployment. 
(t= 6, 12, 24 hours, and once daily to necropsy). 
Step 17. After 1 day, allow the pig to return to normal eating habits. 
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Step 18. Continue collecting blood samples up until necropsy on day 14, or once the 
device detaches collect blood for 7 days after.  
Step 19. On day 14, if the animal is still alive, euthanize it using Fatal-Plus. Collect 
tissues for histology if desired. 
Step 20. Send blood samples to a laboratory for analysis.  
 
Blood Collection: 
• Blood Sample Site/Volume: Jugular vein or other accessible veins, ~2 mL 
• Type of Blood Tubes: K2EDTA 
• Type of Sample: Plasma (~400 µL) 
• Sample Storage and Shipment: -60 to -80°C  
• Each blood sample is collected from the pig jugular vein, or another suitable 
vessel via direct venipuncture, placed into a chilled tube containing K2EDTA as 
the anticoagulant, and inverted several times to mix. Blood samples are kept on 
wet ice until centrifugation. 
 
Plasma Preparation and Storage: 
Blood samples were centrifuged at a temperature of 4°C, at 3,000 x g, for 5 
minutes.  All samples were maintained chilled throughout processing.  Plasma was 
collected into pre-labeled polypropylene tubes and placed in a freezer at -60 to -80°C 
until delivered to PBL Assay Science for analysis. The assay work is described in the in 








Figure 30 Tissue still aspirated after TAM/drug delivery needle has been removed from 
the aspiration system 
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Figure 31. Sutured marker beads for reference of TAM/drug delivery needle during 
radiographs 
 
Animal Housekeeping Information 
Radiographs: The animals were X-rayed at t= 0, 6, 12, 24 hours, and once daily 
until the device was determined to be detached. The device was considered detached by 
using the marker beads as a relative position of the device. Radiographs were not taken 
over the weekends. The radiographs were taken from either lateral side of the animal. 
These were attempted without snaring of the animal but sometimes snaring was required. 
Occasionally the hind leg was superimposed on a radiograph. To counter this, the hind 
leg was pulled back by a technician, while the other took the radiograph. 
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Blood Draws: Blood draws were taken at the same time points as the radiographs but 
continued seven days after the device detached because the half-life of adalimumab is 
seven days. Blood draws were not taken on the weekends, hence the gap in data in the 
results section. The blood draws in this study were taken from the indwelling jugular vein 
by one staff member, while another snared the animal. The catheter was first flushed with 
heparinized saline, the blood was then drawn, and lastly, the catheter was flushed again. 
Medications: Meloxicam was administered every 24 hours for 2-5 days post-
procedure. 
2.7.5 Results 
TAM/Drug Delivery Needle Attachment and Pump Duration 
As described in the design, the TAM and drug delivery needle were integrated into a 
single device, so they attached and detached together. The osmotic pump was sutured 
downstream of the device. In commercial versions of the device, the pump will be 
integrated into the TAM. The device attachment times were determined via X-rays. By 
using the marker beads as a reference, the device's attachment/detachment status could be 
determined. The results of the attachment of this study are shown here (Table 4): 
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Table 4. Attachment duration of drug delivery TAM and osmotic pump in study 1. 
 
 
Since the facilities are shut down on weekends and X-rays are only taken once a 
day, the attachment time is shown as a range of time. The early time is the last known 
time of attachment (Figure 32) and the later time is the next time checked that showed 
certain detachment (Figure 33). All devices were attached to the distal ileum.  
 
Figure 32. A representative x-ray of an attached TAM/Drug delivery needle. The yellow 
square outlines the osmotic pump and the red circle outlines the TAM/Drug delivery 







Exp 1: 7-Day 7 Day Pump/TAM
52 - 100 hours  
(~2.2 - 4.2 days)
52 - 100 hours                                 
(~2.2 - 4.2 days)
Exp 2: 7-Day 7 Day Pump/TAM
24-52 hours      
(~1-2.2 days)
24-52 hours                                      
(~1-2.2 days)
Neg 1 Pump Only- Negative Control NA
52- 75 hours                                   
(~2.2-3.2 days)
Pos 1
Direct Syringe Injection- 
Positive Control
NA NA
Exp 3: 1-Day 1 Day Pump/TAM
53-76 hours 
(~2.2-3.2 days)
53-76 hours                                   
(~2.2-3.2 days)
Exp 4: 1-Day 1 Day Pump/TAM
53-76 hours 
(~2.2-3.2 days)





Figure 33. A representative x-ray of a detached TAM. Only the marker beads are shown 
in the x-ray. 
Drug Delivery 
The plasma concentration levels for the six different animals are shown below (Figure 
34). 
 
Figure 34. Adalimumab plasma concentration levels from in vivo study 1. Exp 1, Exp 2, 
Exp 3, and Exp 4 used the TAM/Drug delivery needle and either a 7-day osmotic pump 
or a 1-day osmotic pump. Pos 1 used a direct needle injection using a manual syringe 
pump (No TAM/Drug delivery device). Neg 1 used only an osmotic pump sutured into 
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This work enabled the veterinarian, staff, and members of the Terry Research Lab 
(TRL) to refine the procedures and analysis of the drug delivery experiments.   
 Due to attachment times being shorter than expected, 1-day osmotic pumps were 
used for the last two animals. Another problem was that the pumps detached from the 
suture, so a later experiment was performed with a new suturing method and this pump 
remained intact for at least five days (directly before holiday shutdown so the pig had to 
be euthanized after five days). This new suture method is explained in more detail in the 
second study.  
Regarding TAM attachment times, all but one TAM was successful in attaching 
for at least two days. During this study, work was being done to optimize the TAM 
attachment time for longer durations. As noted in the x-ray results, the osmotic pump 
detached from the sutures, but a new method has been tested that improves pump 
attachment times to exceed the TAM attachment time (used in vivo Experiment 2).  
The concentration of adalimumab in systemic blood had mixed results. The 
positive control showed relatively high levels of the drug in the blood, which 
demonstrates that adalimumab can be delivered in the submucosa of the small intestine 
and systemically thereafter via a hypodermic needle. Neg 1 showed higher drug 
concentration in the blood than Exp 1 and Exp 2 (7-day pumps) and Exp 4 (1-day pump) 
but had similar results to Exp 3 (1-day pump). The results of the negative control were 
puzzling. Adalimumab may be absorbed across a mucosal surface to some degree, which 
is a reason for the second in vivo experiment. Exp 3 (1-day pump) showed drug in the 
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blood but was at least 10 times less concentrated than the positive control and similar in 
concentration to the negative control. This was a methods development study, so the 
number of pigs in the results did not meet the power for statistical significance.  
We identified several possible reasons for poor drug delivery from the 
experimental groups and explored them in the next trial. These were: 
1. The osmotic function does not perform as anticipated in the small bowel. 
2. The drug injection needle possibly does not penetrate deeply enough. 
3. The TAM and/or osmotic pump possibly detaches early. 
4. Catheter possibly disconnects from the injection needle. 
 
2.8 In vivo Experiment 2 
2.8.1  Introduction    
Improvements were made to address the above problems and potential problems and 
the experiment was repeated. Before running the experiment, testing on pig carcasses was 
performed to further optimize attachment and drug delivery. Many portions of the in vivo 
experiment 2 were the same as the previous study, so unless otherwise noted, assume the 
same procedure. 
2.8.2 Objectives 
1) Penetrate small intestinal tissue with the drug injection needle without 
gastrointestinal perforation 
2) Deliver drug systemically via the submucosa of the small intestine for at least one 
day. This objective is different than the previous study in that we were looking for less 
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time delivering drug and were more focused on proving any drug delivery, even over a 
shorter period.  
2.8.3 Hypothesis 
The hypothesis for this study is the same as the previous study: The drug delivery 
capsule will deliver non-absorbent biologics into the submucosa of the small intestine and 
systemically thereafter. This was a methods development study, so the number of pigs 
outlined in the procedure did not meet the power for statistical significance. 
2.8.4 Materials and Methods 
The perpendicular drug delivery device was used again for this experiment, with 
slight modifications to make the profile smaller (Figure 35). The rigid arm of the drug 
needle that attaches to the catheter was shortened. The overall catheter length from the 
device to the osmotic pump was shortened to about five centimeters.   
 
Figure 35. Smaller profile TAM and drug delivery needle device connected to a catheter. 
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 For this experiment, only 1-day 200 μL osmotic pumps were used for the 
experimental groups. The 1-day pumps were used to ensure the best chance of systemic 
drug delivery. Due to the osmotic pumps detaching early in the first study, they were 
sutured differently in this study. This new suture method allowed the pump to attach to 
the intestine for an extended period and not impact the TAM detachment. The method 
required drilling a hole in the osmotic pump flow moderator cap to create an extra and 
more secure anchoring point (Figure 36). This method was tested in animals and was 
attached for at least five days, meaning the TAM would be the limiting factor since it 
detaches before five days.  
 
Figure 36. Osmotic pump with a hole drilled into the flow moderator cap. 
 
Experimental Design 
 The experimental design was the same as the previous study with some 
exceptions. The breed of pigs was changed to a Duroc Landrace cross breed because the 
previous breed was unavailable. The duration for this study was shortened to about 36 
hours for the inspection of the hardware and tissue in situ following delivery and to 
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collect hardware and tissue. Due to the shorter study length, blood draws were taken 
more frequently. Blood was drawn every six hours during the day. To accommodate the 
more frequent blood draws, arterial catheters were implanted into the animals. 
Experimental Groups 
 The animal groups for this study were:  
1) Negative control (n=1): A 1-day delivery pump was used to directly deliver the 
drug into the lumen of the intestine. Also, an osmotic pump with a long-coiled 
catheter (~ 75 cm) was implanted to measure the function of the pump. This was 
used to show how far the meniscus of the fluid had traveled, thus verifying 
osmotic function (results in Chapter 3). 
2) Positive controls (n=2): The TAM/Drug delivery needle was used in combination 
with a syringe. The device was attached as normal, and then the drug was injected 
manually with a syringe. This is different from the previous approach where only 
a hypodermic needle and a syringe were used, and no TAM.  
3) Experimental groups (n=3): These animals received injections into the submucosa 
using the altered TAM shown in Figure 35.  All devices were attached to a 1-day 
osmotic pump sutured with the new method.  
Surgery/Experimental Procedure 
 The procedure was the same as the previous study except for the following 
alterations to these steps: 
 Step 9: Use the new suture method and the shorter catheter length. 
 Step 16: Blood collections are collected every six hours during the day. 
 Step 18 and 19: The study will only last 36 hours.   
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Blood Collection 
 This time the studies were performed to avoid the weekends so that blood draws 
were taken more often. The total number of blood draws was limited because of the 
available funds for one Enzyme-linked immunosorbent assay (ELISA) kit. Each ELISA 
kit contains 96 wells to tests for adalimumab plasma concentration, however several of 
those wells are occupied for standards and each plasma sample was duplicated. Based on 
this, 34 total blood draws were taken. Due to the limited number of blood draws, each 
animal received five blood draws and the positive controls received an extra two blood 
draws each.  
Plasma Preparation and Storage 
 Same as the previous study 
Animal Housekeeping Information 
 The same as the previous study, but with different duration of housing based on 
the blood samples described in the blood collection paragraph. 
2.8.5 Results 
TAM/Drug Delivery Needle Attachment and Pump Duration 
 The results of the TAM and osmotic pump attachment times are shown in      
Table 5. 
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Table 5. Attachment duration of drug delivery TAM and osmotic pump in study 2. 
 
 As shown in Table 5 all the devices and osmotic pumps were placed in the ileum 
region of the small intestine. All six pigs were healthy and survived to the end of the 
study. All four osmotic pumps placed into an animal stayed sutured in place for the entire 
study (Figure 37). Out of the five animals that had a TAM attached to the small intestine 
during surgery, one (Figure 38) still had the TAM strongly attached during necropsy, 
while another had the TAM slightly attached. All the devices recovered were completely 
intact. The TAM needles used for attachment were still UV glued to the TAM body, they 
kept their appropriate needle angle (Figure 39), and the catheter connecting the drug 










Neg 1 Negative Control
34 hours          
(~1.4 days)
N/A YES
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Figure 37. An osmotic pump was sutured in place during necropsy. 
 









The plasma results for the six different animals are shown below (Figure 40 and 
Figure 41). The samples were run using two different standards. Figure 40 used kit 
standard concentration samples of 0, 5, 10, 25, 50, 100 ng/mL while Figure 41 used a 
more specialized dynamic range of standard samples called “adalimumab injection 
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standards” and they included sample concentrations from 0, 0.0 2, 0.16, 0.8,  , 20, 100 
and 500 ng/mL (Appendix A). 
 
Figure 40. Adalimumab concentration levels using the kit standard-based samples. Exp 1, 
Exp 2, and Exp 3 used the TAM/Drug delivery needle and a 1-day osmotic pump. Pos 1 
and Pos 2 used the TAM/Drug delivery device but instead of an osmotic pump, a manual 
syringe pump was used to inject all 200 µL of drug into the intestinal wall. Neg 1 used 




Figure 41. Adalimumab concentration levels using the modified "adalimumab injection 
standard" based samples. Exp 1, Exp 2, and Exp 3 used the TAM/Drug delivery needle 
and a 1-day osmotic pump. Pos 1 and Pos 2 used the TAM/Drug delivery device but 
instead of an osmotic pump, a manual syringe pump was used to inject all 200 µL of drug 
into the intestinal wall. Neg 1 used only an osmotic pump sutured into the intestinal 
lumen. 
 
Overall, the two graphs had similar trends. Both positive groups showed relatively 
high levels of adalimumab in the plasma, especially Pos 2. Exp 3 showed comparable 
drug levels, suggesting successful systemic biological drug delivery. Neg 1 showed an 
insignificant level of drug and Exp 1 and Exp 2 showed little to no drug delivery.   
2.8.6 Discussion/Conclusions 
Based on the plasma results and hardware finding during necropsy, it was evident that 
this study performed better than the previous study. The plasma results from study 2 
indicated successful drug delivery for both positive controls and one experimental 
treatment while study 1 had no drug delivery for any group. By reducing the post 
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treatment time for study 2, all the components were located easily. This made it easy to 
inspect the hardware for any signs of failure.  In the previous study, the radiographs were 
used to determine if the TAM device or osmotic pump was still attached. The images 
gave a general idea if the TAM or osmotic pump was still attached or at least in the 
general area. However, this method was difficult to confidently say the device was still 
attached. Since this study was shorter than the previous, the device and pump were 
checked for attachment during necropsy. The duration until necropsy varied slightly per 
animal because of different initial surgery times and the amount of blood draws available 
to use in the ELISA kit was limited. Overall, the hardware stayed intact throughout the 
whole study, meaning the catheter disconnecting from the injection needle was 
eliminated as one of the identified possible reasons for poor drug delivery in study 1. 
Generally, the plasma samples are diluted at 1:100, but based on the previous study, it 
turned out most of the samples were falling below the lower limit of quantification 
(LLOQ). Therefore, samples were run in a more concentrated form (1:50). Also, there 
was a possibility that some of the samples would fall above the assay upper limit of 
quantification (ULOQ) of kit standard and a more concentrated standard would allow one 
to measure these samples. To avoid being below the LLOQ and above the ULOQ, the 
assay was run with the additional “adalimumab injection standard.”  
To find the drug concentration levels in the plasma, the optical densities (O.D) of the 
standards were taken and two 4-parameter log fit standard curves were created. The 
formulas were designed to get the standard curves only. The curve fit formula was not 
used to get the sample concentrations directly, but a program called Softmax fitted the 
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samples’ O.D. values to get their respective concentrations.  Concentrations obtained 
from the back-interpolation were multiplied by their respective dilution factors to get the 
final analyte concentration per sample. The raw O.D. values are found in appendix A. 
Although the two graphs showed a similar trend for most groups, Pos 2 had an 
unexplainable difference between the 10-hour and 22-hour timepoints. Figure 41 shows a 
more drastic increase in concentration compared to Figure 40. Also, the last two 
timepoints for Pos 2 and the last time point for Pos 1 were above the ULOQ, therefore the 
software could not calculate their actual concentrations. Similarly, the first time point of 
Exp 1 was lower than the LLOQ. Each in vivo study was performed without statistical 
power to draw conclusions, but there is evidence that suggests further progress is merited.  
Although the drug delivery device showed successful delivery of a biological drug 
in the small intestine, it used a relatively large commercially manufactured osmotic 
pump. To fit an osmotic pump into the final capsule design, a theoretical custom osmotic 
pump was designed.  
  
Chapter 3: Osmotic Pump 
3.1 Introduction 
One of the most important aspects of drug delivery, besides the drug itself, is the 
correct dosage. Underdosing gives poor therapeutic activity, and overdosing can cause 
adverse events [67], [68]. Rate-controlled release systems allow maintaining the drug 
concentration within the body at an optimum level [69], [70]. One of the most successful 
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release systems in recent years is the osmotic pump [71]. Osmotic micropumps require no 
electrical energy, thus enabling drug delivery systems of the smallest size[72]. For these 
reasons, an osmotic pump was chosen for drug delivery. One of the only commercially 
available loadable osmotic pumps today is produced by ALZET and is the model for the 
theoretical custom osmotic pump.  
3.2 Theory of Osmotic Pumps 
Osmosis is one of the most fundamental phenomena in biology, allowing cells to 
balance solute concentrations [73], [74]. Osmosis occurs when two solutions contain 
different concentrations of solutes and are separated by a selectively permeable 
membrane [75], [76]. Solvent molecules travel along a gradient from low concentration 
to high concentration, if the membrane allows [77]. The transfer of molecules continues 
until equilibrium in concentration occurs [78]. If the membrane is semi-permeable, only 
certain molecules can pass, usually the water molecules [79]. In the case of an osmotic 
pump, water flows through the semi-permeable membrane, but the solute (osmotic agent) 
is unable to pass through the semi-permeable membrane [80]. Consequently, it results in 
a hydrostatic pressure difference across the membrane [81]. Osmotic pumps utilize this 
hydrostatic pressure to “push” out the drug from the other end of the pump capsule [82]. 
There are three primary components to an osmotic pump: osmotic agent, solvent, 
and the drug [72]. In our case, the solvent is the water molecules from the intestinal 
chyme, mucous, etc. The drug that is loaded into the osmotic pump could ideally be any 
drug with a reasonable viscosity. ALZET claims their pumps can deliver any viscosity up 
to ketchup (~50,000 cps).[83] This means we are left with the osmotic agent used to 
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“drive” the osmosis. To calculate the osmotic pressure, the van’t Hoff equation (2) is 
used [84].  
 𝝅 = 𝒊𝑪𝑹𝑻                 (2) 
This equation shows the osmotic pressure (𝜋) of a solution is proportional to the 
solute concentration (osmotic agent) and temperature, where C stands for the 
corresponding osmotic agent solute concentration (mol/L), R is the molar gas constant 
(8314 J mol− 1 K− 1), and T the absolute temperature (K). The van't Hoff factor i 
represents the number of moles of solute dissolved in a solution per mole of added solid 
solute (this value is 1 if a solute does not dissociate). When the osmotic pressure is 
known, one can calculate the flow rate of a fluid using equation (3) [85]. 
 𝑱 = 𝑲 × 𝑨 × (𝝈∆𝝅 − ∆𝑷)                    (3)  
where J is the volume transported per unit time, K is the permeability of the membrane, A 
is the effective surface area of the membrane, 𝜎 is the osmotic reflection coefficient of the 
membrane, ∆𝜋 is the difference in osmotic pressure, and ∆𝑃 is the difference in 
hydrostatic pressure. Figure 42 shows the components of a simple osmotic pump [85].  
 
Figure 42. Schematic of an osmotic pump.  
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Knowing the components and the theory of an osmotic pump, we can now take a 
closer look at ALZET’s osmotic pump (Figure 43.) They have three different sizes of 
pumps, a 100 μL, 200 μL, and 2 mL reservoir. Each of these pumps has several different 
release times ranging from one day to four weeks. Our goal was to deliver a drug for 4-7 
days, so these pumps were an excellent product to model. However, we had a very strict 
size constraint and all three of these models were too large. Consequently, we needed to 
design a pump that would be compatible with our TAM design.  
 
Figure 43. ALZET Osmotic Pump.  
Our theoretical pump would use the same components that the ALZET pump 
uses, just with different shapes and sizes. First, their pump uses sodium chloride as an 
osmotic agent, so that would be used in our theoretical pump. The osmotic pressure 
created from sodium chloride at body temperature is over 270,000 mmHg [71].  For our 
system, the drug injection needle was around a total of 6 mm long with an inner diameter 
of 0.159 mm (30 gauge) and two 90-degree elbows. Using these dimensions and a 
velocity of 1 μL day to calculate the pressure loss in the system, the total loss would be 
negligible, nearly 0. The pressure within capillaries is only around 20 mmHg [86], 
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meaning the pressure generated from the pump would certainly overcome any pressure 
loss from the tubing and needle bends and therefore would pump drug into the 
bloodstream.  
ALZET uses a cellulose ester blend as a semi-permeable membrane. They do not 
specify exactly the contents of the blend due to intellectual property, but there is much 
literature about different cellulose ester blends including cellulose acetate, cellulose 
diacetate, cellulose triacetate, cellulose propionate, cellulose acetate butyrate, and 
cellulose ethers [71]. We anticipate our custom pump would use one of the blends. 
ALZET’s design is different than the simple schematic in Figure 43 in that their 
movable portion does not push from one direction, but rather radially contracts to push 
the drug out. The movable portion is a thermoplastic hydrocarbon elastomer. Some 
designs use a piston to push the drug out (Figure 44) [87]. We used this piston-driven 
device for our theoretical pump. 
 
 
Figure 44. Example of a piston-driven osmotic pump.  
3.3 Functional Requirements of Osmotic Pump 
1. Component Materials and Properties 
The osmotic pump used in the final will be designed with non-toxic parts and the osmotic 
pump used in experiments will be a commercially available osmotic pump. 
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2. Drug Chemistry, Manufacturing, and Controls (CMC) 
Parts or materials of the TAM in contact with the drug shall be stable. A limited drug 
shelf life shall not limit the TAM shelf life, and vice versa.  
3. Drug Loading  
The TAM should contain a feature that allows the loading of a drug before going in-vivo.  
4. Manufacturability 
The system shall be manufacturable in a timely fashion on a scale of 100,000 units/year. 
Note: this quantity is different from the cost quantity to make a conservative case in both 
categories. 
5. Drug Payload Description 
The theoretical osmotic pump should work for the following payloads. 
Table 6. Function requirement for drug delivery payload. 
Payload Type Target Concentration Delivery Rate Duration Total Volume
GLP-1 10 μg μL 10 μg day 4-7 days     μL week  
 
6. Drug Payload Material and Viscosity 
The drug will be in a liquid format with viscosity and fluid properties based on the 
commercially available formulation. 
 
3.4 Design of Osmotic Pump 
After each of the components has been selected, the shape and size of the osmotic 
pump were modified to fit within the final capsule design. Based on ALZET’s 
dimensions, the drug reservoir volume is at a minimum of 20% of the pump’s total 
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volume. If the volume of the drug we are trying to deliver in a week is 7 µl, and we 
follow ALZETs drug reservoir to pump volume ratio, our pump size would be about 35 
mm3. As a safety factor, a 30% clearance was given in the design making the total pump 
volume 45 mm3. To satisfy these conditions, a torus-shaped, piston-driven, osmotic pump 
was designed (Figure 45). 
 
Figure 45. Schematic of the torus-shaped osmotic pump 
The volume of a torus is: 
 𝑽 = (𝝅𝒓𝟐)(𝟐𝝅𝑹) 
 
(4) 
where R is the major radius and r is the minor radius. In our design, R is 4 mm and r is 
0.75 mm resulting in a total pump volume of approximately 45 mm3. The thickness of the 
outer shell is 0.15 mm. To insert the drug injection needle a small arc (30-degrees or 
about 8% of the total volume) of the torus was removed (Figure 46), resulting in a final 
pump volume of about 41 mm3. ALZET’s 100 μL pump has a semi-permeable membrane 
thickness of 0.45 mm and an osmotic agent thickness of 0.30 mm. The regions that 
contain the semi-permeable membrane, osmotic agent, and drug are illustrated in the half-
section view in Figure 47. In our design, the semi-permeable region was about 20-
64 
degrees of the pump, which is around 1 mm thick, with a radius of 0.6 mm. The osmotic 
agent is filled between the semi-permeable layer and the piston. The amount of osmotic 
agent required should be tested to determine the delivery rate and duration. The 
biological drug fills the remaining volume from the piston to the hypodermic needle. The 
30-gauge hypodermic needle consists of two 90-degree bends with a total length of 
around 6 mm. Table 7 shows all the components, materials, and dimensions required to 
construct the custom osmotic pump. ALZET’s 100 μL pumps are sold at around $24.00, 
with a lowered assumed unit cost. The components, materials, and overall size of our 
custom osmotic pump are similar to ALZET’s 100 μL pump, therefore we expect our unit 
cost to be lower than $24.00.  The file for the osmotic pump is found here: 
https://unl.box.com/s/wxb06ud6dox4bw222rivbc3po5vaf0zb or Wankum_Ben\Capsule 
Project\Final Device Files for Progenity\osmotic_Pump_file. A detailed drawing with 
dimensions is shown in Figure 48 and the file is found here: 
https://unl.box.com/s/u1yyhetpcx08ovdrmhkplle3mzwgyaar or Wankum_Ben\Capsule 





Figure 46. CAD design of a torus-shaped osmotic pump with a drug injection needle. 
 
Figure 47. Half-section view of the osmotic pump showing the spherical-shaped piston, 
drug location, osmotic agent location, and semi-permeable membrane. 
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Figure 48. Drawing of the osmotic pump. Units are in millimeters. 
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67 
 
3.5 Function of Osmotic Pump in the Intestine 
 To our knowledge, there has been no proof of ALZET’s osmotic pumps being 
used in any portion of the small or large intestine. To prove the feasibility of osmotic 
drug delivery in the intestine, an ALZET 1-day, 200 μL osmotic pump was sutured into 
the ileum. The osmotic pump was loaded with black India ink, primed in saline at 37o C 
for 3 hours, and a 75 cm tube was attached. The meniscus of the ink was measured before 
implantation (Figure 49). The pump and tubing were then sutured into a porcine intestine 
via enterotomy. After surgery, the animal recovered and resumed its normal diet and 
activity for over a day, until it was euthanized for inspection. The pump was found 
sutured in place, the meniscus of India ink was measured (Figure 50), and the volume of 
ink delivered was calculated. The total volume of ink delivered was approximately 220 
μL, which was close to the e pected 200 μL for the lot we received. This e periment 




Figure 49. Pre-implantation of an osmotic pump with India ink meniscus. 
 
Figure 50. Osmotic pump with India ink meniscus after being in a porcine intestine for 




Chapter 4: Discussion and Conclusions 
The overall scientific goal of the research was to utilize subcutaneous needle 
injection methodology used for parenteral systemic biologic drug delivery to solve the 
problem of delivering biologics orally for treating diseases like diabetes, arthritis, or 
cancers. This was to be accomplished by demonstrating proof-of-feasibility of systemic 
biological drug delivery via a needle injection into the submucosa of the small intestine. 
This was completed by integrating the TAM with a commercial off-the-shelf (COTS) 
drug delivery system. The COTS system used to deliver the drug in this work was 
AZLET’s osmotic pumps. The pumps were connected to a hypodermic drug delivery 
needle via a thin, tubed catheter. The drug delivery needle was developed to administer 
the drug into the submucosa of the small intestine. The drug delivery needle was 
designed and integrated into the TAM body and tested on the benchtop. The final design 
of the drug delivery needle was a needle that perpendicularly pierced the intestinal tissue 
upon actuation of the attachment sequence.  
After the delivery needle consistently and successfully performed on excised 
swine tissue, it was tested in live pigs. Two separate tests were performed on six animals 
each. The goal of the studies was to deliver a biological drug (adalimumab) with the 
TAM and drug delivery needle via an osmotic pump. Positive and negative controls were 
used for comparisons. The first study did not go as planned, since the TAM was 
detaching sooner than expected, but the experimental procedure was learned and there 
were still questions to be answered, so the experiment was repeated with modifications. 
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The second study showed much stronger evidence of drug delivery, with both positive 
controls and an experimental group showing adalimumab in the plasma results. Both 
studies were a methods development study, so the number of pigs in the results did not 
meet the power for statistical significance.  
The other goal of this project was to design a custom osmotic pump that could 
theoretically be introduced into the full device. The theory of osmotic pumps was studied 
and ALZET’s commercial osmotic pumps were used as a reference in the design of the 
custom pump. A torus-shaped, piston-driven, osmotic pump was designed to fit within 
the capsule. An ALZET osmotic pump was tested with India ink in the small intestine 
and showed evidence of accurate drug delivery. Although there was no statistical power 
in these experiments, the animal studies showed drug delivery, suggesting an osmotic 
pump can be used for drug delivery, but a full-scale study with statistical power should be 
performed.  
4.1 Future Work 
Drug delivery using injection into the intestinal submucosa with an ingestible 
device is a radical approach for the administration of agents with poor oral 
bioavailability. However, with this approach, the innovation potential is large. 
Specifically, the ability to deliver unmodified drugs, which take years and billions of 
dollars to develop. Although the drug delivery needle showed proof of feasibility to 
systemically deliver drug via injection into the intestinal wall, there were drawbacks to 
the study design. As stated, this study was a methods development study, so future 
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studies should include additional animals to draw more conclusions. Numerous technical 
and regulatory hurdles need to be negotiated before patient trials can be performed. 
One of the main concerns of the capsule designs is how will a swallowed device 
latch on strongly enough to the mucosal surface so that it can perform its complete task. 
At the time of this writing, TRL is working on a coil spring system to provide intimate 
contact with the intestinal wall.  There are risks of full perforation, obstruction, and other 
mechanical complications. These complications will occur but the key is to keep the 
incidence very low during studies. 
 As discussed in the introduction of this work, bioavailability is a major 
benchmark to determine the success of a device. A future study should include an animal 
being administered adalimumab via IV. This would allow one to calculate the 
bioavailability of the device by comparing the AUC of the device to the AUC of an IV 
administration.  
Since attachment times were shorter than expected, future work should be done 
on optimizing TAM attachment time. Once a reliable long-term attachment is achieved, it 
would be interesting to run another drug delivery test.  In vivo study 1 was designed to 
accomplish this and might be useful to rerun after attachment time is lengthened.  
After my work was complete, the new injection needle and TAM were integrated 
into the capsule system that was designed in another phase of the project (Figure 51). The 
capsule system implemented all aspects of the final design, except for the custom osmotic 
pump; a sham pump was used instead. The semi-complete capsule system should be 
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Appendices 
Appendix A:  Standard Curves and Raw Data from In Vivo Experiment 2 
The following tables and figures were provided by PBL Assay Science:  
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Table 8. Adalimumab kit standard curve used to measure adalimumab concentrations for 
plasma samples from groups 136 (Neg 1), 137 (Exp 1), 139 (Exp 2), 140 (Exp 3), 141 








Standard 1 100 1.399 1.374 0.035 2.6 100.409 100.409
1.349
Standard 2 50 1.139 1.116 0.033 2.9 49.963 99.926
1.093
Standard 3 25 0.834 0.826 0.012 1.5 24.52 98.082
0.817
Standard 4 10 0.497 0.516 0.027 5.2 10.595 105.953
0.535
Standard 5 5 0.308 0.299 0.013 4.5 4.7 93.996
0.289




Figure 52. 4-parameter log fit standard curve used to measure adalimumab concentrations 
for plasma samples from groups 136 (Neg 1), 137 (Exp 1), 139 (Exp 2), 140 (Exp 3), 141 
(Pos 1), and 163 (Pos 2). 
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Table 9. Adalimumab ELISA: Group 136 (Neg 1). Measured adalimumab concentrations 
of the samples from group 136 (Neg 1). Values below the LLOQ (5 ng/ml) are marked in 
red. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
136 A 0.027 0.026 0.001 5.4 0.148 7.402
0.025
136 B 0.044 0.043 0.002 5 0.329 16.449
0.041
136 C 0.057 0.056 0.001 2.5 0.491 24.547
0.055
136 D 0.056 0.055 0.002 3.9 0.472 23.621
0.053
136 E 0.056 0.057 0.001 2.5 0.503 25.168
0.058  
 
Table 10. Adalimumab ELISA: Group 137 (Exp 1). Measured adalimumab 
concentrations of the samples from group 137 (Exp 1). Values below the LLOQ (5 
ng/ml) are marked in red. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
137 A 0.012 0.011 0.001 12.9 0.011 0.553
0.01
137 B 0.202 0.191 0.016 8.5 2.546 127.319
0.179
137 C 0.714 0.692 0.032 4.6 17.432 871.582
0.669
137 D 0.646 0.647 0.001 0.2 15.474 773.702
0.648




Table 11. Adalimumab ELISA: Group 139 (Exp 2). Measured adalimumab 
concentrations of the samples from group 139 (Exp 2). Values below the LLOQ (5 
ng/ml) are marked in red. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
139 A 0.419 0.407 0.017 4.2 7.35 367.48
0.395
139 B 0.149 0.151 0.002 1.4 1.861 93.056
0.152
139 C 0.421 0.409 0.018 4.3 7.39 369.502
0.396
139 D 0.412 0.392 0.029 7.4 6.938 346.91
0.371
139 E 0.364 0.364 0.001 0.2 6.224 311.19
0.363  
Table 12. Adalimumab ELISA: Group 140 (Exp 3). Measured adalimumab 
concentrations of the samples from group 140 (Exp 3). Values below the LLOQ (5 
ng/ml) are marked in red and those above the ULOQ (100 ng/ml) are marked in green. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
140 A 0.718 0.716 0.003 0.4 18.586 929.286
0.714
140 B 0.097 0.093 0.006 6.1 0.983 49.137
0.089
140 C 1.499 1.499 0 0 151.412 7570.61
1.499
140 D 1.372 1.439 0.095 6.6 123.165 6158.244
1.506




Table 13. Adalimumab ELISA: Group 141 (Pos 1). Measured adalimumab concentrations 
of the samples from group 141 (Pos 1). Values below the LLOQ (5 ng/ml) are marked in 
red and those above the ULOQ (100 ng/ml) are marked in green. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
141 A 0.036 0.037 0.001 1.9 0.261 13.036
0.037
141 B 1.228 1.27 0.059 4.7 74.563 3728.156
1.312
141 C 1.372 1.459 0.122 8.4 131.429 6571.474
1.545
141 D 1.508 1.454 0.076 5.3 129.452 6472.613
1.4
141 E 1.487 1.524 0.052 3.4 166.098 8304.901
1.561
141 F 1.459 1.571 0.158 10.1 200.317 10015.83
1.683
141 G 1.703 1.684 0.027 1.6 350.093 17504.668
1.665  
Table 14. Adalimumab ELISA: Group 163 (Pos 2). Measured adalimumab concentrations 
of the samples from group 163 (Pos 2). Values below the LLOQ (5 ng/ml) are marked in 
red and those above the ULOQ (100 ng/ml) are marked in green. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
163 A 0.088 0.092 0.005 5.4 0.962 48.08
0.095
163 B 1.524 1.556 0.045 2.9 187.914 9395.716
1.587
163 C 1.558 1.563 0.007 0.5 193.761 9688.074
1.568
163 D 1.513 1.595 0.116 7.3 222.22 11110.981
1.677
163 E 1.567 1.594 0.037 2.4 220.742 11037.106
1.62
163 F 1.668 1.643 0.035 2.2 279.389 13969.457
1.618




Table 15. Additional adalimumab standard curve used to measure adalimumab 
concentrations for plasma samples from groups 136 (Neg 1), 137 (Exp 1), 139 (Exp 2), 








Standard 1 500 1.766 1.555 0.299 19.2 362.648 72.53
1.343
Standard 2 100 1.595 1.424 0.242 17 118.166 118.166
1.253
Standard 3 20 0.921 0.838 0.117 14 18.866 94.331
0.755
Standard 4 4 0.339 0.309 0.043 14 4.294 107.352
0.278
Standard 5 0.8 0.081 0.081 0.001 0.9 0.885 110.577
0.08
Standard 6 0.16 0.025 0.024 0.002 9 0.131 81.956
0.022
Standard 7 0.032 0.011 0.011 0 0 NaN NaN
0.011





Figure 53. 4-parameter log fit standard curve used to measure adalimumab concentrations 
for plasma samples from groups 136 (Neg 1), 137 (Exp 1), 139 (Exp 2), 140 (Exp 3), 141 
(Pos 1), and 163 (Pos 2). 
 
Table 16. Adalimumab ELISA: Group 136 (Neg 1). Measured adalimumab 
concentrations of the samples from group 136 (Neg 1). Values below the LLOQ (0.160 
ng/ml) are marked in red. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
136 A 0.027 0.026 0.001 5.4 0.165 8.234
0.025
136 B 0.044 0.043 0.002 5 0.383 19.15
0.041
136 C 0.057 0.056 0.001 2.5 0.561 28.028
0.055
136 D 0.056 0.055 0.002 3.9 0.541 27.041
0.053
136 E 0.056 0.057 0.001 2.5 0.574 28.686
0.058  
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Table 17. Adalimumab ELISA: Group 137 (Exp 1). Measured adalimumab 
concentrations of the samples from group 137 (Exp 1). Values below the LLOQ (0.160 
ng/ml) are marked in red. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
137 A 0.012 0.011 0.001 12.9 NaN NaN
0.01
137 B 0.202 0.191 0.016 8.5 2.421 121.058
0.179
137 C 0.714 0.692 0.032 4.6 13.272 663.613
0.669
137 D 0.646 0.647 0.001 0.2 11.892 594.579
0.648
137 E 0.747 0.735 0.017 2.3 14.749 737.443  
Table 18. Adalimumab ELISA: Group 139 (Exp 2). Measured adalimumab 
concentrations of the samples from group 139 (Exp 2). Values below the LLOQ (0.160 
ng/ml) are marked in red. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
139 A 0.419 0.407 0.017 4.2 6.1 305.018
0.395
139 B 0.149 0.151 0.002 1.4 1.843 92.162
0.152
139 C 0.421 0.409 0.018 4.3 6.13 306.496
0.396
139 D 0.412 0.392 0.029 7.4 5.799 289.941
0.371
139 E 0.364 0.364 0.001 0.2 5.271 263.561
0.363  
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Table 19. Adalimumab ELISA: Group 140 (Exp 3). Measured adalimumab 
concentrations of the samples from group 140 (Exp 3). Values below the LLOQ (0.160 
ng/ml) are marked in red. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
140 A 0.718 0.716 0.003 0.4 14.087 704.365
0.714
140 B 0.097 0.093 0.006 6.1 1.052 52.587
0.089
140 C 1.499 1.499 0 0 196.28 9813.987
1.499
140 D 1.372 1.439 0.095 6.6 128.757 6437.836
1.506
140 E 1.293 1.395 0.144 10.3 101.585 5079.237
1.497  
Table 20. Adalimumab ELISA: Group 141 (Pos 1). Measured adalimumab concentrations 
of the samples from group 141 (Pos 1). Values below the LLOQ (0.160 ng/ml) are 
marked in red. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
141 A 0.036 0.037 0.001 1.9 0.304 15.198
0.037
141 B 1.228 1.27 0.059 4.7 60.883 3044.143
1.312
141 C 1.372 1.459 0.122 8.4 145.365 7268.227
1.545
141 D 1.508 1.454 0.076 5.3 141.197 7059.838
1.4
141 E 1.487 1.524 0.052 3.4 248.241 12412.032
1.561
141 F 1.459 1.571 0.158 10.1 480.591 24029.547
1.683
141 G 1.703 1.684 0.027 1.6 NaN NaN
1.665  
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Table 21. Adalimumab ELISA: Group 163 (Pos 2). Measured adalimumab concentrations 
of the samples from group 163 (Pos 2). Values above the ULOQ (500 ng/ml) are marked 
in green. 
Sample O.D. Mean O.D. Std. Dev. CV% Concentration Final Conc.
163 A 0.088 0.092 0.005 5.4 1.032 51.58
0.095
163 B 1.524 1.556 0.045 2.9 368.148 18407.405
1.587
163 C 1.558 1.563 0.007 0.5 415.26 20763.02
1.568
163 D 1.513 1.595 0.116 7.3 906.42 45320.985
1.677
163 E 1.567 1.594 0.037 2.4 858.859 42942.952
1.62
163 F 1.668 1.643 0.035 2.2 NaN NaN
1.618
163 G 1.663 1.679 0.022 1.3 NaN NaN
1.694  
Appendix B: Drug delivery TAM fabrication process 
Following are the materials, files, and instructions for building the drug delivery TAM: 
Bill of Materials for Device 
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Table 22. List of parts and suppliers. 
Description Supplier
30 Gauge, ½ inch hypodermic needle Global Medical Products (#48-2015)
Laser-cut TAM needle 316 Full Hard 
Stainless, .008" thickness
Micron Laser, Hillsboro, OR
Small Catheter- Medical grade micro 
vinyl catheter tubing (I.D. x O.D.:  
0.02 ″   0.0 5″   0.69mm   1.1 mm 
Scientific Commodities Inc. (SCI) 
(cat.# bb 1 85 v  a 50′ roll  
Large- Catheter- Medical grade micro 
vinyl catheter tubing (I.D. x O.D.:  
0.011″   0.025″   0.28mm   0.6 mm 
Scientific Commodities Inc. (SCI) 
(cat.# bb 1 85 v 1 50′ roll  
200 μL 1 day delivery osmotic pump 
(other pumps from ALZET may be 
used depending on the volume and 
duration of the study).
Alzet Osmotic Pumps- 2001D
PGN-001 (adalimumab) Progenity  
List of Files for Device 
All files for the fabrication of the drug delivery TAM are found here: 
https://unl.box.com/s/h6evar1gy8prq3eha0vvu18xgptvicxj  
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5j1e6n80   
Inventor model - TAM device 
with hole for drug delivery 
hypodermic needle
6.5 mm 90-degree bend .2 mm bend radius 
https://unl.box.com/s/d6tzdkgwk1rg11dch0nkus6
mllbdtau6 
Inventor model- 6.5mm length, 
90-degree bend, 0.2mm bend 
radius mold
2mm 90-degree bend .2 mm bend radius 
https://unl.box.com/s/b1f52e8kmsy7foq5r7c2entr
nvaevb9y   
Inventor model- 2 mm length, 














List of Tools and Supplies for Device 
Table 24. List of tools and supplies for the TAM. 
Tool/Supplies Description
UV glue
Hold together TAM 
needles and drug delivery 
needle to TAM device
UV light Cure UV glue
Microscope 
Confirm bend angles for 








3D print material for 
hypodermic needle and 





Step 1. 3D print the following files with their specified material: 
a. TAM (VeroClear)-  
https://unl.box.com/s/x4r9dbslauuft5hmzdbagfpd5j1e6n80  
b. 6.5 mm bending mold (RGD450)- 
https://unl.box.com/s/d6tzdkgwk1rg11dch0nkus6mllbdtau6 
c. 2.0 mm bending mold (RGD450)- 
https://unl.box.com/s/b1f52e8kmsy7foq5r7c2entrnvaevb9y 





Bending TAM needle 
Step 2. Remove the TAM needle from the laser cut sheet (Figure 54). 
Step 3. Place the non-bent TAM needle (Figure 55) onto the bottom 30-degree 
TAM needle bending mold. (Figure 56). 
Step 4. Place the top 30-degree TAM needle bending mold over the TAM needle 
and press down (Figure 57). 
Step 5. Separate the two molds and remove the bent TAM needles from the top 
bending mold (Figure 58). 
Step 6. Take the 30-degree bent TAM needle (Figure 59) and confirm its angle 
with a microscope.  
Bending drug delivery needle 
Step 7. Bend the ½ inch 30-gauge hypodermic needle (Figure 60) 6.5 mm at 90-
degrees by using the 3D printed mold (Figure 61). Confirm the 90-degree bend 
with a microscope (Figure 62).  
Step 8. Next, bend the hypodermic needle 90-degrees again with the 2 mm mold 
(Figure 63). The needle should now have two 90-degree bends.  Confirm the 
angles with a microscope.  
Step 9. Snap off the yellow Luer lock from the hypodermic needle (Figure 64). 
Assembling Device 
 
Step 10. Place UV glue onto the bottom of the bent TAM needle and set it in the 
slot on the TAM device. Cure the UV glue with a UV light (Figure 65). 
Step 11. Slide the bent hypodermic needle into the TA  device’s pre-existing hole 
(Figure 65). 
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Step 12. Cut 2 cm of the small catheter and place it over the hypodermic needle 
arm. 
Step 13. Bend down the hypodermic needle arm and catheter and fasten them to the 
TAM device with UV glue (Figure 66). 
Step 14. Insert the distal end of the small catheter into 2 cm of the large catheter. 
Use UV glue to hold them in place (Figure 67). 
Step 15. Lastly, attach the osmotic pump to the distal end of the large catheter. 
Step 16. Fill and prime the osmotic pump according to ALZET’s guidelines: 
https://www.alzet.com/guide-to-use/filling-priming-alzet-pumps/  
Step 17.  The device is then ready to be inserted into the intestine, attached, and to 
deliver the drug according to the outline in “In vivo E periment 1” of this 
document.   
 
 




Figure 55. Non-bent TAM needle. 
 
Figure 56. Non-bent TAM Needle in bottom 30-degree bending mold. 
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Figure 57. TAM Needle in 30-degree bending molds. 
 
Figure 58. Bent TAM Needle in top 30-degree bending mold. 
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Figure 59. 30-degree TAM needle. 
 




Figure 61. Hypodermic needle in bending mold. 
 
 




Figure 63. Hypodermic needle bent 90-degrees twice. 
 
 




Figure 65. TAM with a drug injection needle (shorten arm used). 
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Figure 66. Needle arm bent down and glued to a small catheter. 
 
Figure 67. The final device without the osmotic pump. 
 
 
